EMA Panel Backs Approval of Lutetium [177Lu] oxodotreotide for GEP-NETs

July 21, 2017 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Lutetium [177Lu] oxodotreotide for the treatment of patients with unresectable or metastatic, progressive, well-differentiated (grade 1 and grade 2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The positive CHMP opinion is based on the phase III NETTER-1 trial, which … (leggi tutto)